Stemtech Corp (STEK) Stock Forecast Oct. 9, 2026
Analysis updated on Oct. 9, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
Stemtech Corp (STEK) stock forecast summary
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for STEK is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
STEK price chart and AI forecast
How STEK ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Stemtech Corp (STEK) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
Valuation & Market
| Metric | STEK | Rank |
|---|---|---|
| EPS | $0.00 | – |
Profitability & Margins
| Metric | STEK | Rank |
|---|---|---|
| ROA | -100.0% | 8/8 |
| ROIC | 23.4% | 3/6 |
| Operating Margin | -132.8% | 7/7 |
| Net Margin | -225.8% | 7/8 |
| EBT Margin | -189.4% | 7/8 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | STEK | Rank |
|---|---|---|
| Current Ratio | 0.05x | 7/7 |
| Quick Ratio | 0.02x | 7/7 |
| Interest Coverage | -101.5x | 7/7 |
| Working Capital | -$11M | 5/7 |
Cash Flow
| Metric | STEK | Rank |
|---|---|---|
| Operating Cash Flow | -$1M | 7/8 |
Operational Efficiency
| Metric | STEK | Rank |
|---|---|---|
| Inventory Turnover | 1.4x | 7/7 |
| Days Inventory | 257 days | 1/7 |
| Payables Period | 4881 days | 1/6 |
Income Statement
| Metric | STEK | Rank |
|---|---|---|
| Operating Income | -$1M | 5/7 |
| Net Income | -$3M | 6/8 |
| R&D Expense | $0.00M | – |
| Cost of Goods Sold | $440K | 7/8 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $570K | |
| Cash & Short-term Investments | $250K | |
| Accounts Receivable | $0.00M | |
| Inventory | $310K | |
| Total Liabilities | $11M | |
| Short-term Debt | $5M |
STEK quarterly financials and insider trading
Stemtech Corp (STEK) industry peers
Companies classified under the same SEC industry code as Stemtech Corp (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere STEK sits on the market map
Stemtech Corp (STEK) stock news
Loading...
Stemtech Corp (STEK) stock forecast FAQ
What is the Stemtech Corp (STEK) stock forecast?
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
How accurate are Stemtech Corp stock predictions?
A per-ticker accuracy statistic for STEK is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Stemtech Corp forecasts updated?
Stemtech Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 9, 2026.
Which companies are Stemtech Corp's industry peers?
8 issuers in our coverage, STEK included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cencora, Inc. (COR), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Hwh International Inc. (ESYN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.